Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease - High Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting around 20% of the world s population LONDON, Silence Therapeutics plc , AIM: SLN and Nasdaq: SLN ( Silence or the Company ), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced a new review publication on the prevention of cardiovascular disease linked to high lipoprotein(a) - Lp(a) - levels in the latest issue of Cardiovascular Research,